Muscular and cardiac manifestations in a Duchenne-carrier harboring a dystrophin deletion of exons 12-29

Josef Finsterer1,*, Claudia Stöllberger2, Birgit Freudenthaler2, Desiree De Simoni3, Romana Höftberger3, Klaus Wagner4

1 Krankenanstalt Rudolfstiftung, Vienna, Austria; 2 2nd Medical Department with Cardiology and Intensive Care Medicine, Krankenanstalt Rudolfstiftung, Vienna, Austria; 3 Institute of Neurology, Medical University of Vienna, Vienna, Austria; 4 Institute for Human Genetics, Medical University of Graz, Graz, Austria.

Summary
Female carriers of mutations in the dystrophin gene (DMD-carriers) may manifest clinically in the skeletal muscle, the heart, or both. Cardiac involvement may manifest before, after, or together with the muscle manifestations. A 46y female developed slowly progressive weakness of the lower and upper limbs with left-sided predominance since age 26y. Muscle enzymes were repeatedly elevated and muscle biopsy showed absence of dystrophin. MLPA analysis revealed a deletion of exons 12-29. After starting steroids at age 39y, she developed palpitations and exertional dyspnoea. Cardiac MRI at age 41y revealed mildly reduced systolic function, a slightly enlarged left ventricle, mild hypokinesia of the entire myocardium, and focal, transmural late gadolinium enhancement (LGE) of the midventricular lateral wall. She did not tolerate beta-blockers but profited from ivabradine and lisinopril. In conclusion, muscle manifestations in DMD-carriers with deletions of exons 12-29 may start years before cardiac involvement becomes clinically apparent. Progressive worsening of systolic function in DMD-carriers is attributable to progressive myocardial fibrosis, as demonstrated by LGE. Steroids may trigger the development of cardiac disease in DMD-carriers.

Keywords: Duchenne muscular dystrophy, cardiac involvement, heart failure, dystrophin, X-chromosomal, carrier, myopathy

1. Introduction
Due to skewed X-chromosome inactivation of one of the two X-chromosomes, female carriers of X-chromosomal gene mutations may present with variable clinical manifestations, ranging from normal to a phenotype like in males (1). This is also the case for carriers of deletions or point mutations in the dystrophin gene causing Duchenne muscular dystrophy (DMD) (DMD-carriers) (1). DMD-carriers are usually asymptomatic. However, some of the DMD-carriers become symptomatic and develop a progressive DMD-like phenotype. This is the case if the majority of the X-chromosomes carrying the wild-type allele is inactivated. The higher the percentage of inactivated wild-type dystrophin genes, the more severe will the phenotype of manifesting DMD-carriers be. Some of the DMD-carriers may even resemble male patients with DMD (1). Since dystrophin mutations not only manifest in the skeletal muscles but also in the myocardium, DMD males and DMD-carriers may develop variable degrees of cardiac disease (2). Cardiac involvement in DMD usually starts with ECG abnormalities until patients develop dilated cardiomyopathy. In DMD-carriers dilated cardiomyopathy may be the initial manifestation of the skewed X-inactivation. Here we present a DMD-carrier with muscle and myocardial manifestations since adulthood and compare them with clinical and genetic findings of previous reports.

2. Case Report
The patient is a 46y female, height 172 cm, weight...
Intractable & Rare Diseases Research Advance Publication

64 kg, with an uneventful history until age 25y, when she developed difficulties climbing stairs. Muscle enzymes were repeatedly elevated (Table 1). During the further course she developed slowly progressive proximal muscle weakness with left-sided predominance and experienced recurrent falls without losing consciousness. The patient was first admitted to the authors’ institution at age 29y. Work-up for the above mentioned abnormalities at age 29y with informed consent of the patient revealed scapula alata, weakness (M4-) and wasting of the shoulder girdle and proximal upper limb muscles, and proximal weakness and reduced tendon reflexes of the lower limbs. Muscle biopsy at age 29y from the right deltoid muscle revealed myopathic features with atrophic and hypertrophic muscle fibres, necrotic fibres, proliferation of endomysial connective tissue (Figure 1A), absence of dystrophin on the sarcolemma of some fibres (mosaic pattern) (Figure 1B), and upregulation of utrophin (Figure 1C). At age 37y genetic testing of blood lymphocyte DNA by means of multiplex ligation-dependent probe amplification (MLPA) revealed a heterozygote deletion of exons 12-29 in the dystrophin gene (NM_004006.2:c.(1331+1_1332-1)_(4071+1_4072-1)del). According to the Leiden DMD reading frame checker this mutation leads to an out-of-frame deletion (http://www.dmd.nl/). At age 39y she had experienced a right-sided tibial shatter fracture after a fall when going down a stair. At age 43y she underwent surgery for left-sided clubfoot. She was regularly smoking 20 cigarettes/d since age 18y. The family history was positive for death from DMD at age 15y (nephew), myocardial infarction (mother), lung carcinoma (father), and uterus carcinoma (sister) (Figure 2). She had been taking aprednisolon (initially 25mg/d after some weeks 5mg/d) between age 39y and age 43y. Clinical neurologic examination at age 46y revealed slow and slightly dysarthric voice, scapula alata, bilateral diffuse weakness (M4- to M5-) with distal and left-sided predominance on both upper limbs, diffuse wasting of the shoulder girdle and upper limb muscles with proximal and left-sided predominance, bilaterally reduced tendon reflexes, hypotonia, a fixed flexion contracture of the left elbow, diffuse weakness (M3 to M5-) with proximal, flexor, and left-sided predominance of the pelvic girdle and lower limb muscles, diffuse wasting with proximal predominance, and reduced freedom of motion of the left ankle joint, reduced tendon reflexes, and hypotonia. The Gower sign was positive.

Routine cardiologic investigation for cardiac involvement at age 26y showed a normal electrocardiogram (ECG) but slightly enlarged left atrium on echocardiography. ECG at age 29y was normal again. Since initiation of steroids at age 39y, she experienced exertional dyspnoea and palpitations, manifesting as sinustachycardia on ECG. Upon administration of beta-blockers at age 41y she developed vertigo and low blood pressure, which is why they were replaced by ivabradine (7.5 mg/d), which was well tolerated and effective.

Table 1. Blood chemical investigations indicating affection of the skeletal muscle

| Parameter      | RL   | 10/97 | 11/00 | 05/04 | 05/04 | 03/07 | 05/16 | 08/16 |
|----------------|------|-------|-------|-------|-------|-------|-------|-------|
| CK             | 0 - 70 U/L | 562   | 625   | 2101  | 1365  | 1968  | 371%  | nd    |
| GOT            | 0 - 35 U/L | nd    | nd    | 76    | 60    | 58    | nd    | 26    |
| GPT            | 0 - 35 U/L | nd    | nd    | 68    | 61    | 50    | nd    | 20    |
| LDH            | 120 - 240 U/L | 198   | nd    | 286   | 267   | 324   | nd    | 200   |
| Aldolase       | 0 - 7.6 U/L | 7.4   | nd    | nd    | 13.9  | nd    | nd    | nd    |
| Myoglobin      | 0 - 70 μg/L | nd    | nd    | 331   | 234   | nd    | nd    | nd    |

CK: creatine-kinase, GOT: glutamate-oxalate transaminase, GPT: glutamate-pyruvate transaminase, *: Reference limit 26-145 U/L, #: reference limit: < 170 U/L, &: reference limit GOT: < 31 U/L, reference limit GPT: < 34 U/L, §: reference limit 135-235 U/L, %: reference limit < 247 U/L, %: reference limit 20-180 U/L, nd: not done.

Figure 1. Muscle biopsy from the deltoid muscle shows myopathic features with variation in fibre size and phagocytes invading necrotic fibres. (A, H&E; arrow: phagocytes; asterisks: hypertrophic fibres), some fibres lacking dystrophin next to fibres with normal dystrophin expression (mosaic pattern) (B, dystrophin; arrows: fibres lacking dystrophin expression), and upregulation of utrophin on the sarcolemma (C, utrophin; arrows). ×200

www.irdrjournal.com
d) was added. At age 45y she consulted a cardiologist because of recurrent chest pain. ECG showed left anterior hemiblock (LAH) and right bundle branch block (RBBB). Echocardiography showed a borderline systolic function (EF 50%), slightly enlarged left atrium, and minimal mitral insufficiency. Since chest pain resolved under non-steroidal analgesics, it was interpreted as vertebrogenic. At follow-up, one month later, she again complained about chest pain and exertional dyspnoea. ECG was unchanged since the previous recording. Echocardiography showed borderline systolic function (EF 50%), mildly enlarged atria, diastolic dysfunction, abnormal mobility of the interventricular septum, and mitral insufficiency. Serum N-terminal pro-brain-natriuretic peptide (NT-pro-BNP) levels were measured several times between age 42y until 46y and were always slightly elevated ranging between 206-244 ng/L (normal < 169 ng/L). Her last medication included lisinopril (2.5 mg/d) and ivabradine (7.5 mg/d).

3. Discussion

DMD-carriers have been previously reported to predominantly manifest phenotypically in the skeletal muscle or myocardium (Table 2) (2). Muscle disease in DMD-carriers may have a broad range of manifestations. Muscle disease can be quite variable and may manifest with only creatine-kinase (CK)-elevation (3,17,22,25,29), with exercise intolerance (14), muscle cramps (20), or

Cardiac MRI (cMRI) at age 41y revealed mildly reduced systolic function, a slightly enlarged left ventricle, mild hypokinesia of the entire myocardium with a left ventricular ejection fraction (EF) of 50%, and focal, transmural late gadolinium enhancement (LGE) of the midventricular lateral wall (arrow).
Concerning cardiac disease in DMD-carriers, frequency, type, degree, and onset can be quite variable. In a study of 210 DMD-carriers, 60% had cardiac involvement. In a Japanese study of 16 DMD-carriers, 31% had cardiac symptoms, ECG abnormalities were found in 56%, and 75% had echocardiographic abnormalities (3). One of these carriers underwent endomyocardial biopsy showing absence of dystrophin in 75% of the fibers (3). Cardiac disease in DMD-carriers includes myocardial fibrosis, ECG abnormalities, systolic dysfunction, or heart failure. Rarely, DMD-carriers may develop dilated cardiomyopathy (Table 2) (5,6), even as the initial cardiac manifestation (5). In a single DMD-carrier sudden cardiac death was reported (7). In a study of 20 DMD-carriers of whom only 2 had muscle symptoms, 13 had at least one cMRI abnormality, 4 (20%) had reduced systolic function, and 13 (65%) had LGE (8). All LGE-positive patients had non-ischemic LGE with subepicardial involvement of the lateral free wall being the most frequent pattern (8). In another study of 20 DMD-carriers one third had LGE (9). Muscle and cardiac symptoms were not different between those with and without LGE (9). In a cMRI study of 7 DMD-carriers, LGE was found in four of them (10). LGE was subendocardial but two patients had focal LGE in the left inferolateral wall (10). In the majority of the cases, cardiac involvement in DMD-carriers does not develop before adulthood. In a study of 23 DMD-carriers under age 16y, none had any abnormality on extensive cardiologic work-up (11). However, in some patients cardiac disease may already develop in childhood. In a 10yo DMD-carrier, systolic dysfunction was recognised already at age 10y in the absence of muscle manifestations (12). Frequently, cardiac involvement may precede muscular abnormalities (3,10,13). Cardiac dysfunction in DMD-carriers may be triggered by pregnancy (13) or steroids, as shown in our case. In accordance with previous reports (Table 2), the currently presented patient manifested cardiologically with heart failure, reduced systolic function, LGE, and ECG abnormalities.

Whether the degree of muscle and cardiac involvement

Table 2. Phenotypic and genotypic characteristics of published DMD-carriers with or without skeletal muscle involvement and With or without cardiac disease

| NOP | Mutation | MM | MB | Myocardium | Ref. |
|-----|----------|----|----|------------|-----|
| 15 | del (n = 10), 17-18, dup (n = 12) | Weakness (n = 7) | Dystrophin ↓ | Normal (n = 15) | (14) |
| 20 | del (n = 13), dup (n = 7) | Symptoms (n = 2) | cMRI ab (n = 13) | (8) |
| 8 | nm | Normal | nm | LGE (n = 7) | (9) |
| 1 | nm | Weakness | nm | dilation, HF | (15) |
| 1 | nm | Normal | nm | HF | (13) |
| 1 | nm | lipid ↑ on MRI | nm | nm | (16) |
| 1 | nm | CK ↑ | nm | ECG, echo an, TnT ↑ | (17) |
| 5 | dup 2 | nm | LGE (n = 5), HF (n = 1) | (18) |
| 1 | Not detected | Weakness, CK ↑ | Dystrophin ↓ | LGE | (19) |
| 15 | del 45-52, 50, 46-49, 51-7, 8-13, dup 43, 17-18, 45-59, PM 14, 15, 47, ins 8 | Weakness (n = 14) | nm | ECG, echo an | (20) |
| 7 | nm | Weakness (n = 5) | nm | LGE (n = 4) | (10) |
| 1 | dup 2 | Normal | nm | HF, dystrophin ↓ | (21) |
| 1 | dup 1-6 | CK ↑ | Dystrophin ↓ | HF | (22) |
| 38 | del 48-50, 3-7, dup 8-9 | Weakness (n = 13) | an (n = 2) | dCMP (n = 5) | (23) |
| 1 | ins 43 | Weakness | nm | HF | (24) |
| 1 | nm | CK ↑ | nm | Arrhythmias | (25) |
| 1 | nm | Normal | nm | HF, HTX | (26) |
| 1 | nm | Normal | nm | dCMP, dystrophin ↓ | (27) |
| 1 | del 50-52 | Normal | Dystrophin ↓ | dCMP, HTX | (28) |
| 2 | nm | CK ↑ | nm | Dystrophin ↓, HF | (29) |
| 16 | nm | Normal | nm | ECG, echo an | (30) |
| 1 | nm | Normal | nm | HF | (31) |
| 1 | Not detected | Normal | nm | Dystrophin ↓ | (32) |

MM: muscle manifestations, MB: muscle biopsy, LGE: late gadolinium enhancement, HF: heart failure, dCMP: dilated cardiomyopathy, PM: point mutation, nm: not mentioned, an: abnormal, *: during general anesthesia

with muscle weakness and wasting (14,15,19,20). Other DMD-carriers may develop wasting without muscle weakness and the more severely affected patients may develop slowly progressive weakness, which may be asymptomatic at onset, as in the presented case. In a study of 16 DMD-carriers, 87% had CK-elevation in the absence of muscle symptoms or signs (3). Occasionally, muscle involvement may histologically mimic myositis (4). In accordance with these previously described manifestations (Table 2), the currently presented patient manifested with muscle weakness and wasting and CK-elevation.
only depends on the degree of X-chromosome inactivation or additionally depends on the location and size of the dystrophin deletion has been only poorly investigated. Exons most frequently deleted in DMD-carriers include numbers > 45 (Table 2). Though there have been reports according to which deletions in the N-terminal domains are predominantly associated with cardiac involvement, these reports have not been confirmed in later studies. From Table 2 it is not possible to draw a strong correlation between the location of the mutation within the dystrophin gene and the type and degree of muscle or cardiac involvement.

In conclusion, this case shows that muscle manifestations in DMD-carriers may start years before cardiac involvement becomes apparent. Muscle and cardiac manifestations may slowly progress over years. Systolic dysfunction, heart failure, and conduction defects are attributable to myocardial fibrosis, manifesting as LGE. Application of steroids may trigger defects in DMD-carriers. Informed consent: Informed consent was obtained from the described participant.

Note: Informed consent: Informed consent was obtained from the described participant

References

1. Carsana A, Frisson G, Intri M, Tremolaterra MR, Giovanni Savarese G, Scapagnini G, Esposito G, Santoro L, Salvatore F. A 15-year molecular analysis of DMD/BMD: Genetic features in a large cohort. Front Biosci (Elite Ed). 2010; E2:547-558.

2. Comi LI, Nigr G, Politano L, Petretta VR. The dyscardiopathy of Duchenne/Becker consultands. Int J Cardiol. 1992; 34:297-305.

3. Ueda Y, Kawai H, Adachi K, Nanto U, Saito S. Cardiac dysfunction in female gene carriers of Duchenne muscular dystrophy. Rinsho Shinkeigaku. 1995; 35:1191-1198. (in Japanese)

4. Yoon J, Kim SH, Ki CS, Kwon MJ, Lim MJ, Kwon SR, Joo K, Moon GP, Park W. Carrier woman of Duchenne muscular dystrophy mimicking inflammatory myositis. J Korean Med Sci. 2011; 26:587-591.

5. Hirama S, Maekawa K, Hikata T, Takagaki K, Shoji K. Female carrier of Duchenne muscular dystrophy presenting with secondary dilated cardiomyopathy: A case report. J Cardiol. 2001; 38:35-40. (in Japanese)

6. Barison A, Aquaro GD, Passino C, Falorni M, Balbarini A, Lombardi M, Pasquali L, Emdin M, Siciliano G. Cardiac magnetic resonance imaging and management of dilated cardiomyopathy in a Duchenne muscular dystrophy manifesting carrier. J Neurol. 2009; 256:283-284.

7. Marchesi S, Alkhimovitch O, Cirirrione C, Galloni G, Pelligrini A, Russo TE, Ferrario G. Typical electrocardiogram in atypical context. Or, when history and electrocardiogram are conclusive for a complex diagnosis. Ital Heart J Suppl. 2002; 3:949-951. (in Italian)

8. Florian A, Rösch S, Bietenbeck M, Engel M, Stymann J, Waltenberger J, Sechtem U, Yilmaz M. Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their first-degree male relatives: A comparative cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2016; 17:326-333.

9. Lang SM, Slugh S, Mazur W, Sticka JJ, Rattan MS, Jeffery LS, Taylor MD. Myocardial fibrosis and left ventricular dysfunction in duchenne muscular dystrophy carriers using cardiac magnetic resonance imaging. Pediatr Cardiol. 2015; 36:1495-1501.

10. Iwase T, Takao S, Akae M, et al. Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy. Heart Asia. 2010; 2:52-55.

11. Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord. 2003; 13:129-132.

12. Martinez HR, Pignatelli R, Belmont JW, Craigen WJ, Jefferys JL. Childhood onset of left ventricular dysfunction in a female manifesting carrier of muscular dystrophy. Am J Med Genet A. 2011; 155A:3025-3029.

13. Cheng VE, Prior DL. Peripartum cardiomyopathy in a previously asymptomatic carrier of Duchenne muscular dystrophy. Heart Lung Circ. 2013; 22:677-681.

14. Papa R, Madia F, Bartolomeo D, Tracca F, Pedemonte M, Travieso M, Broda P, Bruno C, Zara F, Minetti C, Fiorillo C. Genetic and early clinical manifestations of females heterozygous for Duchenne/Becker muscular dystrophy. Pediatr Neurol. 2016; 55:58-63.

15. Ishii H, Nakamura K, Nagahama H, Matsumura M, Endo J, Nishimura M. Mitral valve replacement for a manifesting carrier of duchenne muscular dystrophy. Kyobu Geka. 2015; 68:94-97. (in Japanese)

16. Forbes SC, Lott DJ, Finkel RS, Sennesac C, Byrne BJ, Sweeney H, Walter GA, Vandenborne K. MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy. Neuromuscul Disord. 2012; 22(suppl 2):S111-S121.

17. De Pooter J, Vandeweghe J, Vonck A, Loth P, Geraedts J. Elevated troponin T levels in a female carrier of Duchenne muscular dystrophy with normal coronary angiogram: A case report and review of the literature. Acta Cardiol. 2012; 67:253-256.

18. Walcher T, Steinbach P, Spiess J, Kunze M, Gradinger R, Walcher D, Bernhardt P. Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: A cardiovascular magnetic resonance study. Eur J Radiol. 2011; 80:115-119.

19. Finsterer J, Stöllberger C, Avanzini M, Bastovansky A, Wexberg P. Late gadolinium enhancement as subclinical myocardial involvement in a manifesting Duchenne carrier. Int J Cardiol. 2011; 146: 231-232.

20. Soltanzadeh P, Frier MJ, Dunn D, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord. 2010; 20:499-504.

21. Walcher T, Kunze M, Steinbach P, Spierfeld AD, Burgstahler C, Hombach V, Torzewski J. Cardiac involvement in a female carrier of Duchenne muscular dystrophy. Int J Cardiol. 2010; 138:302-305.

22. Tunteeratum A, Witoonpanich R, Phudhicharoonrat S, Eulsuansontornwattana J, Pinsuthiwong S, Sriharn K, Sura T. Congestive heart failure with rhabdomyolysis and acute renal failure in a manifesting female carrier of Duchenne muscular dystrophy with duplication of dystrophin gene. J Clin Neuromuscul Dis. 2009; 11:49-53.
23. Hoogerwaard EM, Ginjaar IB, Bakker E, de Visser M. Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy. Neurology. 2005; 65:1984-1986.
24. Miyamoto A, Taguchi K, Hieda S, Kawamura M, Fukuchi K, Gomi K. Detection of micro mutation in dystrophin gene of DMD female carrier. Rinsho Byori. 2004; 52:493-499. (in Japanese)
25. Kerr TP, Duward A, Hodgson SV, Hughes E, Robb SA. Hyperkalaemic cardiac arrest in a manifesting carrier of Duchenne muscular dystrophy following general anaesthesia. Eur J Pediatr. 2001; 160:579-580.
26. Davies JE, Winokur TS, Aaron MF, Benza RL, Foley BA, Holman WL. Cardiomyopathy in a carrier of Duchenne's muscular dystrophy. J Heart Lung Transplant. 2001; 20:781-784.
27. Ogata H, Nakagawa H, Hamabe K, Hattori A, Ishikawa Y, Ishikawa Y, Saito M, Minami R. A female carrier of Duchenne muscular dystrophy complicated with cardiomyopathy. Intern Med. 2000; 39:34-38.
28. Melacini P, Fanin M, Angelini A, Pegoraro E, Livi U, Daniele GA, Hoffman EP, Thiene G, Dalla Volta S, Angelini C. Cardiac transplantation in a Duchenne muscular dystrophy carrier. Neuromuscul Disord. 1998; 8:585-590.
29. Rüchardt A, Eisenlohr H, Lydtin H. Myocardial involvement in carrier states for Duchenne muscular dystrophy. A rare cause of supraventricular arrhythmia. Dtsch Med Wochenschr. 1998; 123:930-935. (in German)
30. Kinoshita H, Goto Y, Ishikawa M, Uemura T, Matsumoto K, Hayashi YK, Arahata K, Nonaka I. A carrier of Duchenne muscular dystrophy with dilated cardiomyopathy but no skeletal muscle symptom. Brain Dev. 1995; 17:202-205.
31. Watanabe K, Izumi T, Natsui M, Matsubara N, Miyakita Y, Koyama S, Inomata T, Suzuki M, Shibata A. Dystrophin negative skeletal and myocardial muscle cells in a carrier of Duchenne's muscular dystrophy. Eur Heart J. 1993; 14:989-992.
32. Schmidt-Achert M, Fischer P, Müller-Felber W, Mudra H, Pongratz D. Heterozygotic gene expression in endomyocardial biopsies: A new diagnostic tool confirms the Duchenne carrier status. Clin Investig. 1993; 71:247-253.

(Received January 6, 2018; Revised February 25, 2018; Accepted March 21, 2018)